Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:ONC)

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire 2 days ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

PR Newswire 3 days ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

PR Newswire 9 days ago

Oncolytics Biotech approved to expand pancreatic cancer program

Trevor Abes  9 days ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

PR Newswire 9 days ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

PR Newswire 10 days ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire April 30, 2024

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

PR Newswire April 25, 2024

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

PR Newswire April 11, 2024
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA MEETING

Haha you spent all that time and effort to type that garbage on a Saturday? 
Azzak34 - 30 minutes ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA MEETING

lonc17: Back to you in your own words "Noted. Now get lost."
Noteable - 1 hour ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA MEETING

MC:  Thanks for agreering to meet with us.  FDA: Sure, no problem. How can we help? MC:  We're exploring the...
lonc17 - 1 hour ago

RE:RE:RE:RE:RE:RE:RE:RE:FDA MEETING

The reporting on the outcome of ONCY's FDA Type C meeting will likely happen next week, and would strategically precede ASCO 2024...
Noteable - 2 hours ago

RE:RE:RE:RE:RE:RE:RE:FDA MEETING

The 2024 ASCO Annual Meeting is scheduled for May 31-June 4, 2024.
Noteable - 2 hours ago

RE:RE:RE:RE:RE:RE:FDA MEETING

" .... by the end of May, before ASCO 2024." On Thursday Matt Coffey clarified matters on the timing that the FDA Type C...
Noteable - 2 hours ago
View more Bullboard ››

World Copper Ltd

World Copper Ltd

World Copper Ltd. is a Canada-based exploration stage junior mining company, which is engaged in the identification ...
View More »